Dr. Peters Discusses Ongoing Research With Trastuzumab Deruxtecan in NSCLC

Solange Peters, MD,​ PhD, chief, Medical Oncology Service, ​chair, Thoracic Oncology, Lausanne University Hospital, Lausanne, Switzerland, discusses ongoing research with ​fam-trastuzumab deruxtecan​-nxki (Enhertu; ​DS-8201) in patients with HER2-mutated non–small cell lung cancer (NSCLC).

​Findings from the ​phase 2 DESTINY-Lung01 trial ​could provide the rationale that is needed to move trastuzumab deruxtecan into the first-line setting in this patient population, ​says Peters. ​Historically, EGFR and ALK inhibitors have demonstrated significantly improved progression-free survival when moved into the frontline setting, and the same could be true for trastuzumab deruxtecan.

Additionally, moving the therapy into the frontline setting may provide a more accurate representation of the associated toxicities, explains Peters. Treatments given in the second- and later-lines settings could display residual toxicities from earlier treatments, such as immunotherapy in this setting, concludes Peters.